Paper86136
Antitumour effect of cimetidine.
Armitage JO and 1 other. Lancet, 1979. Cited by 77 papers, by iCite.
Cite this record
ConductScience Library. Antitumour effect of cimetidine. Papers, record 86136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/86136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics20
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Cimetidine | Major topic |
| Guanidines | Major topic |
| Neoplasms | Major topic |
| Aged | |
| Brain Neoplasms | |
| Carcinoma | |
| Carcinoma, Bronchogenic | |
| Female | |
| Gastroesophageal Reflux | |
| Head and Neck Neoplasms | |
| Humans | |
| Lung Neoplasms | |
| Male | |
| Middle Aged | |
| Neck Muscles | |
| Neoplasm Metastasis | |
| Neoplasm Regression, Spontaneous | |
| Radiography | |
| Soft Tissue Neoplasms |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30250558 | Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway. | Oncol Lett | 2018 | https://conductscience.org/library/papers/30250558 | PubMed |
| 27739410 | Artemisinin and Its Derivatives as a Repurposing Anticancer Agent: What Else Do We Need to Do? | Molecules | 2016 | https://conductscience.org/library/papers/27739410 | PubMed |
| 25525463 | Repurposing drugs in oncology (ReDO)-cimetidine as an anti-cancer agent. | Ecancermedicalscience | 2014 | https://conductscience.org/library/papers/25525463 | PubMed |
| 22895966 | Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. | Cochrane Database Syst Rev | 2012 | https://conductscience.org/library/papers/22895966 | PubMed |
| 20375653 | Cysteinyl leukotriene receptor antagonists inhibit tumor metastasis by inhibiting capillary permeability. | Keio J Med | 2010 | https://conductscience.org/library/papers/20375653 | PubMed |
| 11870499 | Cimetidine in colorectal cancer--are the effects immunological or adhesion-mediated? | Br J Cancer | 2002 | https://conductscience.org/library/papers/11870499 | PubMed |
| 8353038 | Growth of cultured human glioma tumour cells can be regulated with histamine and histamine antagonists. | Br J Cancer | 1993 | https://conductscience.org/library/papers/8353038 | PubMed |
| 8102321 | Inhibition of prostaglandin E2 formation and histamine action in cancer immunotherapy. | Cancer Immunol Immunother | 1993 | https://conductscience.org/library/papers/8102321 | PubMed |
| 8063222 | Gastric cancer risk after vagotomy. | Gut | 1994 | https://conductscience.org/library/papers/8063222 | PubMed |
| 7828988 | Cimetidine inhibits in vivo growth of human colon cancer and reverses histamine stimulated in vitro and in vivo growth. | Gut | 1994 | https://conductscience.org/library/papers/7828988 | PubMed |
| 6511283 | The role of histamine antagonists on the development of experimental cancer in the rat. | Ir J Med Sci | 1984 | https://conductscience.org/library/papers/6511283 | PubMed |
| 6281143 | Mitogen stimulation of peripheral blood lymphocytes of duodenal ulcer patients during treatment with cimetidine or ranitidine. | Gut | 1982 | https://conductscience.org/library/papers/6281143 | PubMed |
| 6128996 | Histamine receptor antagonism and anti-tumour activity. | Br J Cancer | 1982 | https://conductscience.org/library/papers/6128996 | PubMed |
| 3350837 | Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma. | J Cancer Res Clin Oncol | 1988 | https://conductscience.org/library/papers/3350837 | PubMed |
| 3160225 | In vivo and in vitro anti-tumour activity of dimaprit. | Agents Actions | 1985 | https://conductscience.org/library/papers/3160225 | PubMed |
| 3114265 | Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. | J Cancer Res Clin Oncol | 1987 | https://conductscience.org/library/papers/3114265 | PubMed |
| 2457300 | Pathophysiological significance of the distribution of histamine receptor sub-types: a proposed dual role for histamine in inflammation and type I hypersensitivity reactions. | Agents Actions | 1988 | https://conductscience.org/library/papers/2457300 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/86136
GET https://conductscience.org/api/papers/v1/86136/authors